Amazing overall response rate of 74% because of CVA21.
"suggesting the additive therapeutic benefit of CVA21 with ipilimumab.".
- Forums
- ASX - By Stock
- VLA
- Gilead buys Kite Pharma for $11.9 BN
Gilead buys Kite Pharma for $11.9 BN, page-27
-
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add VLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online